HomeNDC LookupRxCUI directory › RxCUI 2678894

Givinostat 8.86 MG/ML Oral Suspension — RxCUI 2678894

RxNorm drug concept · Semantic clinical drug
RxCUI 2678894 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2678894
Official nameGivinostat 8.86 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asgivinostat 8.86 MG/mL (equivalent to givinostat HCl monohydrate) Oral Suspension
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)3,659 prescriptions · 26 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Givinostat 8.86 MG/ML Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Givinostat 8.86 MG/ML Oral Suspension RxCUI 2678894

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Givinostat 2678889
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Duvyzat 2678895
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Givinostat Oral Suspension 2678893
    • Givinostat Oral Liquid Product 2678892
    • Givinostat Oral Product 2678891
    • Givinostat Oral Suspension [Duvyzat] 2678899
    • Duvyzat Oral Liquid Product 2678898
    • Duvyzat Oral Product 2678897
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Givinostat 8.86 MG/ML SCDC · 2678890
  • Givinostat Oral Suspension SCDF · 2678893
  • Givinostat Oral Liquid Product SCDG · 2678892
  • Givinostat Oral Product SCDG · 2678891

Brand-Name Concepts

  • Givinostat 8.86 MG/ML Oral Suspension [Duvyzat] SBD · 2678900
  • Givinostat 8.86 MG/ML [Duvyzat] SBDC · 2678896
  • Givinostat Oral Suspension [Duvyzat] SBDF · 2678899
  • Duvyzat Oral Liquid Product SBDG · 2678898
  • Duvyzat Oral Product SBDG · 2678897
  • Duvyzat BN · 2678895

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2678894 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
11797-0110-02 1 BOTTLE in 1 CARTON (11797-110-02) / 140 mL in 1 BOTTLE (1... DUVYZAT Italfarmaco SPA 2024-03-21
Observed labelers: Italfarmaco SPA (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.